title: [Fine structure of megakaryocyte precursor cells (promegakaryoblasts) derived from smears and sections of bone marrow tissue in patients with chronic myeloid leukemia and so-called primary osteomyelofibrosis with accompanying thrombocythemia].
abstract: An immunomorphometric study (antiglycoprotein III a - Y2/51) was performed on routinely processed trephine biopsies in 24 patients with chronic myeloid leukemia (CML) as well as so-called primary osteomyelofibrosis (OMF) to determine the frequency and fine structure of promegakaryoblasts (PMB). With respect to controls, there was a significant increase in megakaryocytes in both entities with an orderly expansion of the precursor subpopulation in CML, but a relative decrease in OMF. In comparison with smears of aspirates, sizes of PMB were reduced by about 25% (factor 1.4) in the corresponding bone marrow sections.
authors.affiliation: Institut für Pathologie, Universität Köln.
authors.forename: J
authors.initials: J
authors.lastname: Thiele
authors.forename: S
authors.initials: S
authors.lastname: Wagner
authors.forename: C
authors.initials: C
authors.lastname: Sander
authors.forename: D
authors.initials: D
authors.lastname: Dienemann
authors.forename: R
authors.initials: R
authors.lastname: Weuste
authors.forename: H P
authors.initials: HP
authors.lastname: Bertsch
authors.forename: R
authors.initials: R
authors.lastname: Fischer
authors.forename: H
authors.initials: H
authors.lastname: Stein
mesh_terms: D001853:Bone Marrow / Q000473:pathology*; D006412:Hematopoietic Stem Cells / Q000473:pathology / Q000648:ultrastructure*; D006801:Humans; D015464:Leukemia, Myelogenous, Chronic, BCR-ABL Positive / Q000097:blood / Q000473:pathology*; D008533:Megakaryocytes / Q000473:pathology / Q000648:ultrastructure*; D010019:Osteomyelitis / Q000097:blood / Q000473:pathology*; D013921:Thrombocytopenia / Q000150:complications / Q000473:pathology*
vernacular_title: Die Feinstruktur der frühen megakaryozytären Vorläuferzellen (Promegakaryoblasten) im Ausstrich- und Schnittpräparat bei Patienten mit chronischer myeloischer Leukämie und sog. primärer Osteomyelofibrose mit begleitender Thrombozythämie.